Nasus Pharma Ltd priced its initial public offering at $8.00 a share, offering 1,250,000 ordinary shares, to list on the NYSE American under the symbol NSRX. It filed a Form F-1 registration statement for an initial public offering on July 9, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, August 14, 2025).
Sell to companies like Nasus Pharma Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · What it is: Registration statement filed (foreign issuer) · F-1
- · What it is: Final prospectus filed: the offering is priced · 424B4
- · What it is: Registration statement amended (foreign issuer) · F-1/A
- · What it is: Registration statement amended (foreign issuer) · F-1/A
- · What it is: Registration statement filed (foreign issuer) · F-1
Nasus Pharma Ltd filed a Form F-1 registration statement for an initial public offering on 2025-07-09. It has amended it 2 times. It filed its final prospectus on 2025-08-14, at a public offering price of $8.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Nasus Pharma Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by BALYASNY ASSET MANAGEMENT L.P. | 9.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Balyasny Asset Management L.P. | 9.99% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G, by Funicular Funds, LP | 5.2% of the class | 5%+ stakes | Source |
| February 25, 2026 | Form D, private offering | $15M sold | Form D page | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Dr. Ronnie Hershman | 15.3% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Dr. Dalia Megiddo | 20.9% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13G, by Udi Gilboa | 21.1% of the class | 5%+ stakes | Source |
| August 20, 2025 | Stake report, Schedule 13G, by Capital Point Ltd. | 6.35% of the class | 5%+ stakes | Source |
Check before you invest in Nasus Pharma Ltd: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Nasus Pharma Ltd and the records around it.
Nasus Pharma Ltd elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Feb 2026
- Who owns it
Companies that share a holder
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
- Balyasny Asset Management L.P. also filed stake reports on 31 other companies: Beyond Air, Inc. (Aug 2026), Camp4 Therapeutics Corp. (Aug 2026), CELLECTAR BIOSCIENCES, INC. (Aug 2026)
Also filing to list on the NYSE American
IPO filings on the NYSE American in Q1 2026, newest first.
- Option Therapeutics Inc. (Mar 2026)
- SWOL Holdings Inc. (Jan 2026)
- MIXED MARTIAL ARTS GROUP LTD (Jan 2026)
- Edison Oncology Holding Corp (Jan 2026)
- Signing Day Sports, Inc. (Jan 2026)
Watch Nasus Pharma Ltd
Get an email when Nasus Pharma Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Nasus Pharma Ltd?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Nasus Pharma Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Nasus Pharma Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our Ordinary Shares are listed on the NYSE American LLC, or NYSE American, under the symbol “NSRX”.From the F-1 filed 2026-03-02
Shares offered
We are offering 1,250,000 ordinary shares, no par value, or Ordinary Shares, at a public offering price of $8.00 per Ordinary Share.From the 424B4 filed 2025-08-14
Offering price
We are offering 1,250,000 ordinary shares, no par value, or Ordinary Shares, at a public offering price of $8.00 per Ordinary Share.From the 424B4 filed 2025-08-14
Use of proceeds
We intend to use the net proceeds from the February 2026 Private Placement for our ongoing clinical development of NS002 for anaphylaxis treatment, the initiation of first-in-human studies for other products in our pipeline, working capital and general corporate purposes.From the F-1 filed 2026-03-02
Net loss or income
Our net loss for the years ended December 31, 2024 and 2023 were $1.5 million and $1.1 million, respectively, and $1.3 million and $0.9 million for the six months ended June 30, 2025 and 2024, respectively.From the F-1 filed 2026-03-02
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-07-09 | Registration statement filed (foreign issuer) | F-1 |
| 2025-07-28 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-08-07 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-08-14 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-03-02 | Registration statement filed (foreign issuer) | F-1 |
Tools for this story
Each opens in a new tab, filled in for Nasus Pharma Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.